Abstract
Purpose
The use of receptor-targeted antibodies conjugated to photosensitizers is actively being explored to enhance treatment efficacy. To facilitate clinical testing, we evaluated cetuximab conjugated to IRDye700DX (IR700) in cynomolgus macaques.
Procedures
Total IR700 and intact cetuximab-IR700 were measured in 51 tissues at 2 and 14 days after intravenous injection of 40 and 80 mg/kg cetuximab-IR700, respectively, and compared with an unlabeled cetuximab-dosed control group (two each per sex per time point per group).
Results
The IR700 retrieved from all tissues at 2 and 14 days after dosing was estimated at 34.9 ± 1.8 and 2.53 ± 0.67 % of the total dose, respectively. The tissues with the highest levels of intact cetuximab-IR700 at 2 days after dosing were the blood, lung, and skin. Formalin-fixed paraffin-embedded tissue sections at 2 days after dosing showed the highest IR700 signals in the axillary lymph node, mammary gland, and gall bladder.
Conclusions
Both IR700 and intact cetuximab-IR700 biodistributions were consistent with known epidermal growth factor receptor (EGFR) expression, and changes between 2 and 14 days were consistent with rapid metabolism and excretion of the cetuximab-IR700.
Similar content being viewed by others
References
van Dam GM, Themelis G, Crane LM et al (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 17:1315–1319
Zinn KR, Korb M, Samuel S et al (2015) IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol 17:49–57
Day KE, Sweeny L, Kulbersh B et al (2013) Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol 15:722–729
Heath CH, Deep NL, Sweeny L et al (2012) Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol 19:3879–3887
Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB et al (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52:1778–1785
Korb ML, Hartman YE, Kovar J et al (2014) Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. J Surg Res 188:119–128
van Dongen GA, Visser GW, Vrouenraets MB (2004) Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 56:31–52
Mitsunaga M, Ogawa M, Kosaka N et al (2011) Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 17:1685–1691
de Boer E, Warram JM, Hartmans E et al (2014) A standardized light-emitting diode device for photoimmunotherapy. J Nucl Med 55:1893–1898
Mitsunaga M, Nakajima T, Sano K et al (2012) Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer 12:1471–2407
Nakajima T, Sano K, Choyke PL, Kobayashi H (2013) Improving the efficacy of photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics 3:357–365
Rogers SJ, Harrington KJ, Rhys-Evans P et al (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24:47–69
Giusti RM, Shastri KA, Cohen MH et al (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577–583
Kim H, Chaudhuri TR, Buchsbaum DJ et al (2007) High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 6:866–875
de Boer E, Warram JM, Tucker MD et al (2015) In vivo fluorescence immunohistochemistry: localization of fluorescently labeled cetuximab in squamous cell carcinomas. Sci Rep 5:10169
Tichauer KM, Samkoe KS, Gunn JR et al (2014) Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging. Nat Med 20:1348–1353
Acknowledgments
This work was supported by Aspyrian Therapeutics LLC, the UAB Comprehensive Cancer Center small animal imaging shared facility (5P30CA013148), and an equipment loan from LI-COR Biosciences. Authors would like to thank Miguel Garcia-Guzman for his input in this study.
Compliance with Ethical Standards
ᅟ
Conflict of Interest
Dr. K. R. Zinn reports grants from Aspyrian Therapeutics, during the conduct of the study.
Ethical Approval
All applicable institutional and/or national guidelines for the care and use of animals were followed.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Figure 1
(PDF 2947 kb)
Rights and permissions
About this article
Cite this article
de Boer, E., Samuel, S., French, D.N. et al. Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques. Mol Imaging Biol 18, 232–242 (2016). https://doi.org/10.1007/s11307-015-0892-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-015-0892-y